source
- BioXcel files for Chapter 11 bankruptcy, selling assets to Teva for up to $125 MBioXcel Therapeutics announced it has filed for Chapter 11 bankruptcy and plans to sell all of its assets. Teva Pharmaceuticals will serve as the stalking horse bidder, proposing an upfront paymen…
- AstraZeneca and Amgen’s Tezspire eyes Dupixent’s EoE stronghold after late-stage trial winAnalysts note that AstraZeneca and Amgen have secured a late‑stage trial win for Tezspire, positioning the drug as a possible challenger to Dupixent in eosinophilic esophagitis (EoE). Dupixent re…